Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro

被引:137
作者
Wyde, PR
Chetty, SN
Jewell, AM
Boivin, G
Piedra, PA
机构
[1] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA
[3] Univ Laval, Reg Virol Lab, Res Ctr Infect Dis, Quebec City, PQ, Canada
[4] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
关键词
RSV; hN4PV; human metapneumovirus; antiviral; respiratory syncytial virus; ribavirin; IVIG; JNJ2408068;
D O I
10.1016/S0166-3542(03)00153-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human metapneumovirus (hMPV) is a newly recognized pathogen that like its better-known relative, human respiratory syncytial virus (hRSV). appears to be ubiquitous and an important cause of respiratory disease in diverse subpopulations. No antivirals or vaccines are currently approved for the treatment or prevention of hMPV infections. However, ribavirin is licensed to treat serious hRSV-induced infections in children and immune globulin designed for intravenous administration (IVIG) and palivizumab (Synagis(TM)), a humanized monoclonal antibody preparation, have been utilized as alternatives to vaccines for preventing or reducing the severity of infections caused by this virus. Because both ribavirin and IVIG have broad viral specificities, studies were performed to compare the ability of these two agents to inhibit the replication of hRSV and hMPV in tissue culture-based assays. Two experimental chemotherapeutic agents (i.e. VP14637 and JNJ2408068) and different antibody preparations were included in this testing for comparison. Ribavirin and the IVIG utilized were found to have equivalent antiviral activity against hMPV and hRSV. In contrast, except for antisera specifically raised against hMPV. all of the other materials tested had marked activity only against hRSV. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 45 条
[1]  
ANDRIES, 2000, P 40 INT C ANT AG CH
[2]  
[Anonymous], TXB PEDIAT INFECT DI
[3]  
BALZARINI J, 1993, J BIOL CHEM, V268, P24591
[4]   Respiratory syncytial virus immune globulin: Decisions and costs [J].
Barton, LL ;
Grant, KL ;
Lemen, RJ .
PEDIATRIC PULMONOLOGY, 2001, 32 (01) :20-28
[5]   Virological features and clinical manifestations associated with human metapneumovirus:: A new paramyxovirus responsible for acute respiratory-tract infections in all age groups [J].
Boivin, G ;
Abed, Y ;
Pelletier, G ;
Ruel, L ;
Moisan, D ;
Côte, S ;
Peret, TCT ;
Erdman, DD ;
Anderson, LJ .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (09) :1330-1334
[6]  
BRADLEY JS, 1990, ANTIMICROB AGENTS CH, V34, P68
[7]   ANTIVIRAL ACTIVITIES OF 5-ETHYNYL-1-BETA-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE AND RELATED-COMPOUNDS [J].
DECLERCQ, E ;
COOLS, M ;
BALZARINI, J ;
SNOECK, R ;
ANDREI, G ;
HOSOYA, M ;
SHIGETA, S ;
UEDA, T ;
MINAKAWA, N ;
MATSUDA, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :679-684
[8]  
DeVincenzo JP, 1996, BONE MARROW TRANSPL, V17, P1051
[9]   RESPIRATORY SYNCYTIAL VIRUS-INFECTION IN IMMUNOCOMPROMISED ADULTS [J].
ENGLUND, JA ;
SULLIVAN, CJ ;
JORDAN, MC ;
DEHNER, LP ;
VERCELLOTTI, GM ;
BALFOUR, HH .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (03) :203-208
[10]  
Englund Janet A., 1997, American Journal of Medicine, V102, P61, DOI 10.1016/S0002-9343(97)00014-4